Philippe Aftimos’s, Director of the Innovative Therapies Clinic at Jules Bordet Institute, post on X, highlighting an article on ovarian function suppression and its impact in breast cancer care.
Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared Philippe Aftimos’s post, adding:
“Ovarian function suppression is arguably the most important advancement for ER+ young women with breast cancer, markedly reducing recurrence.
Now more trials on how to support side effects for these women thrown into early menopause.”
Title: Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials
Author: Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Other articles featuring Sarah Sammons and Philippe Aftimos on OncoDaily.